Related Experiment Videos
Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies
J L Schultze1, J G Gribben, L M Nadler
1Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Current Opinion in Oncology
|November 18, 1998
Summary
Adoptive transfer of antigen-specific T cells shows promise for treating B-cell malignancies, offering a new immunotherapy approach. Preclinical studies suggest this T-cell therapy is ready for clinical evaluation in patients.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- Standard therapies for B-cell malignancies often fail to achieve a cure for most patients.
- Immunotherapy, including active and passive approaches, is gaining prominence due to the identification of tumor-antigen-derived peptides.
- Research is shifting towards novel strategies beyond traditional idiotype-based vaccination.
Purpose of the Study:
- To review the potential of adoptive transfer of antigen-specific T cells for treating B-cell malignancies.
- To evaluate the feasibility and efficacy of this T-cell therapy approach.
- To discuss potential challenges and future directions for clinical application.
Main Methods:
- Review of murine in vivo models and preclinical experimental data.
- Analysis of strategies involving adoptive transfer of autologous or allogeneic antigen-specific T cells.
- Discussion of obstacles and considerations for clinical translation.
Main Results:
- Preclinical evidence supports the readiness of adoptive T-cell transfer for clinical investigation.
- Antigen-specific T cells represent a viable therapeutic avenue for B-cell malignancies.
- The approach holds potential for both autologous and allogeneic applications.
Conclusions:
- Adoptive transfer of antigen-specific T cells is a promising immunotherapy strategy for B-cell malignancies.
- Further clinical evaluation is warranted to establish feasibility and efficacy.
- Overcoming potential obstacles is crucial for successful implementation of this therapy.